Table 2. Changes in the percentage of cells staining positively for Ki-67 after treatment with exemestane plus celecoxib (EXE–COXIB arm) or exemestane alone (EXE arm).

	EXE–COXIB arm (n=13)	EXE arm (n=14)	P-value of differences between arms
Baseline (%)	12.65 (10.45–16.93)	10.98 (9.01–15.13)	0.43
Post treatment (%)	2.94 (2.33–5.36)	6.14 (5.19–10.81)	<0.02
Relative change: baseline/post treatmenta	4.31 (2.98–7.61)	1.79 (0.85–4.63)	<0.004
Change from baseline P-value	<0.002	<0.02

Abbreviations: COXIB=celecoxib; EXE=exemestane.

Values are given as the geometric means (95% confidence interval).

The Ki-67 expression at post-therapy residual histology was significantly lower in both EXE–COXIB arm (P<0.002) and the EXE arm (P<0.02). The reduction in the combination arm was significantly greater than in single agent (P<0.004).

^aRelative size of baseline to post-treatment percentages.